Though many researchers are focusing on AXL as a putative ZIKV entry receptor and developing therapeutic target, studies have revealed that ZIKV entry and subsequent replication are not solely dependent on the AXL receptor (38–40), limiting the possibility of AXL and other TAM (Tyro, AXL, and Mer) receptors for therapeutic targeting against ZIKV infection. Here, AXL is linked to Zika virus infectious disease.